Search Results

There are 3283 results for: content related to: Combining Naltrexone and Prazosin in a Single Oral Medication Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone

  1. Specific and Nonspecific Effects of Naltrexone on Goal-Directed and Habitual Models of Alcohol Seeking and Drinking

    Alcoholism: Clinical and Experimental Research

    Volume 37, Issue 7, July 2013, Pages: 1100–1110, Rachel A. Hay, Joshua H. Jennings, Dawnya L. Zitzman, Clyde W. Hodge and Donita L. Robinson

    Version of Record online : 7 FEB 2013, DOI: 10.1111/acer.12081

  2. Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals

    Alcoholism: Clinical and Experimental Research

    Volume 39, Issue 9, September 2015, Pages: 1832–1841, Dennis D. Rasmussen, Carrie L. Kincaid and Janice C. Froehlich

    Version of Record online : 11 AUG 2015, DOI: 10.1111/acer.12828

  3. Effects of Naltrexone on Neural and Subjective Response to Alcohol in Treatment-Seeking Alcohol-Dependent Patients

    Alcoholism: Clinical and Experimental Research

    Volume 38, Issue 12, December 2014, Pages: 3024–3032, Primavera A. Spagnolo, Vijay A. Ramchandani, Melanie L. Schwandt, Lishu Zhang, Sara K. Blaine, Julie M. Usala, Kristie A. Diamond, Monte J. Phillips, David T. George, Reza Momenan and Markus Heilig

    Version of Record online : 7 JAN 2015, DOI: 10.1111/acer.12581

  4. 5-HTTLPR Moderates Naltrexone and Psychosocial Treatment Responses in Heavy Drinking Men Who Have Sex with Men

    Alcoholism: Clinical and Experimental Research

    Volume 38, Issue 9, September 2014, Pages: 2362–2368, Andrew C. H. Chen, Christine M. Davis, Christopher W. Kahler, Alexis N. Kuerbis, Jonathan Covault, Henry R. Kranzler and Jon Morgenstern

    Version of Record online : 28 JUL 2014, DOI: 10.1111/acer.12492

  5. Human Laboratory Paradigms in Alcohol Research

    Alcoholism: Clinical and Experimental Research

    Volume 36, Issue 6, June 2012, Pages: 972–983, Jennifer G. Plebani, Lara A. Ray, Meghan E. Morean, William R. Corbin, James MacKillop, Michael Amlung and Andrea C. King

    Version of Record online : 6 FEB 2012, DOI: 10.1111/j.1530-0277.2011.01704.x

  6. Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone

    Clinical & Experimental Ophthalmology

    Volume 42, Issue 2, March 2014, Pages: 159–168, Ian S Zagon, Joseph W Sassani, Jessica A Immonen and Patricia J McLaughlin

    Version of Record online : 29 JUL 2013, DOI: 10.1111/ceo.12144

  7. You have free access to this content
    Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

    Cancer

    Volume 113, Issue 1, 1 July 2008, Pages: 193–201, Allan Lipton, Richard Cook, Fred Saad, Pierre Major, Patrick Garnero, Evangelos Terpos, Janet E. Brown and Robert E. Coleman

    Version of Record online : 5 MAY 2008, DOI: 10.1002/cncr.23529

  8. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness

    Addiction

    Volume 108, Issue 9, September 2013, Pages: 1628–1637, Evgeny Krupitsky, Edward V. Nunes, Walter Ling, David R. Gastfriend, Asli Memisoglu and Bernard L. Silverman

    Version of Record online : 24 MAY 2013, DOI: 10.1111/add.12208

  9. Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalent

    Journal of Pharmaceutical Sciences

    Volume 94, Issue 4, April 2005, Pages: 828–836, Dana C. Hammell, Elzbieta I. Stolarczyk, Mitch Klausner, Mohamed O. Hamad, Peter A. Crooks and Audra L. Stinchcomb

    Version of Record online : 25 FEB 2005, DOI: 10.1002/jps.20238

  10. Transdermal delivery of naltrexone and its active metabolite 6-β-naltrexol in human skin in vitro and guinea pigs in vivo

    Journal of Pharmaceutical Sciences

    Volume 94, Issue 9, September 2005, Pages: 1965–1975, Kalpana S. Paudel, Buchi N. Nalluri, Dana C. Hammell, Satyanarayana Valiveti, Paul Kiptoo, Mohamed O. Hamad, Peter A. Crooks and Audra L. Stinchcomb

    Version of Record online : 28 JUL 2005, DOI: 10.1002/jps.20398

  11. Interleukin-21 and tumor necrosis factor-α are critical for the development of autoimmune gastritis in mice

    Journal of Gastroenterology and Hepatology

    Volume 28, Issue 6, June 2013, Pages: 982–991, Hisayo Nishiura, Satoru Iwamoto, Masahiro Kido, Nobuhiro Aoki, Ryutaro Maruoka, Aki Ikeda, Tsutomu Chiba and Norihiko Watanabe

    Version of Record online : 22 MAY 2013, DOI: 10.1111/jgh.12144

  12. You have free access to this content
    Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats

    Basic & Clinical Pharmacology & Toxicology

    Volume 116, Issue 6, June 2015, Pages: 524–528, Yasushi Torii, Yoshitaka Goto, Shinji Nakahira, Shunji Kozaki, Ryuji Kaji and Akihiro Ginnaga

    Version of Record online : 17 DEC 2014, DOI: 10.1111/bcpt.12351

  13. You have free access to this content
    Structurally conserved α-neurotoxin genes encode functionally diverse proteins in the venom of Naja sputatrix

    FEBS Letters

    Volume 553, Issue 3, October 23, 2003, Pages: 333–341, Kandiah Jeyaseelan, Siew Lay Poh, Ramkishen Nair and Arunmozhiarasi Armugam

    Version of Record online : 3 OCT 2003, DOI: 10.1016/S0014-5793(03)01039-1

  14. Intramuscular extended-release naltrexone: current evidence

    Annals of the New York Academy of Sciences

    Volume 1216, Issue 1, January 2011, Pages: 144–166, David R. Gastfriend

    Version of Record online : 27 JAN 2011, DOI: 10.1111/j.1749-6632.2010.05900.x

    Corrected by:

    Corrigendum for Ann. N. Y. Acad. Sci. 1216: 144–166

    Vol. 1224, Issue 1, 207, Version of Record online: 12 APR 2011

  15. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis

    Clinical Endocrinology

    Volume 78, Issue 6, June 2013, Pages: 844–851, Shunsuke Yamada, Kazuhiko Tsuruya, Hisako Yoshida, Masatomo Taniguchi, Naoki Haruyama, Shigeru Tanaka, Masahiro Eriguchi, Toshiaki Nakano and Takanari Kitazono

    Version of Record online : 6 APR 2013, DOI: 10.1111/cen.12070

  16. You have free access to this content
    Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory destrusor overactivity

    FEMS Immunology & Medical Microbiology

    Volume 51, Issue 1, October 2007, Pages: 201–211, Jae-Chul Lee, Teruhiko Yokoyama, Hyun-Jung Hwang, Hideyuki Arimitsu, Yumiko Yamamoto, Makiko Kawasaki, Tomoko Takigawa, Kouichi Takeshi, Atsushi Nishikawa, Hiromi Kumon and Keiji Oguma

    Version of Record online : 10 AUG 2007, DOI: 10.1111/j.1574-695X.2007.00301.x

  17. Adolescent Social Isolation as a Model of Heightened Vulnerability to Comorbid Alcoholism and Anxiety Disorders

    Alcoholism: Clinical and Experimental Research

    Volume 40, Issue 6, June 2016, Pages: 1202–1214, Tracy R. Butler, Anushree N. Karkhanis, Sara R. Jones and Jeffrey L. Weiner

    Version of Record online : 7 MAY 2016, DOI: 10.1111/acer.13075

  18. You have free access to this content
    Pharmacogenetics of alcohol, nicotine and drug addiction treatments

    Addiction Biology

    Volume 16, Issue 3, July 2011, Pages: 357–376, Jessica E. Sturgess, Tony P. George, James L. Kennedy, Andreas Heinz and Daniel J. Müller

    Version of Record online : 1 MAR 2011, DOI: 10.1111/j.1369-1600.2010.00287.x

  19. Fluvastatin as a Micropore Lifetime Enhancer for Sustained Delivery Across Microneedle-Treated Skin

    Journal of Pharmaceutical Sciences

    Volume 103, Issue 2, February 2014, Pages: 652–660, Priyanka Ghosh, Nicole K. Brogden and Audra L. Stinchcomb

    Version of Record online : 6 JAN 2014, DOI: 10.1002/jps.23844

  20. Development of Naltrexone Supersensitivity During Food-Maintained Responding Enhances Naltrexone's Ability to Reduce Ethanol-Maintained Responding

    Alcoholism: Clinical and Experimental Research

    Volume 31, Issue 1, January 2007, Pages: 39–47, Keith L. Williams

    Version of Record online : 15 DEC 2006, DOI: 10.1111/j.1530-0277.2006.00272.x